Spero Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $7,819 | $6,017 | $4,204 | $71,827 |
Gross Profit | 13,469 | 6,015 | 9,267 | 71,789 |
EBITDA | -18,593 | -19,059 | -13,890 | 50,570 |
EBIT | -19,061 | -13,982 | 50,532 | |
Net Income | -17,727 | -17,862 | -12,669 | 51,191 |
Net Change In Cash | 7,819 | 6,017 | 4,204 | 71,827 |
Free Cash Flow | 12,763 | -18,744 | 5,938 | -17,493 |
Cash | 76,290 | 63,527 | 82,271 | 76,333 |
Basic Shares | 54,124 | 53,957 | 53,524 | 53,108 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $96,735 | $48,579 | $18,256 | $9,330 |
Gross Profit | 96,368 | 47,032 | 17,139 | 9,330 |
EBITDA | 25,771 | -42,263 | -87,170 | -78,352 |
EBIT | 25,404 | -43,810 | -88,287 | -79,113 |
Net Income | 22,806 | -48,028 | -91,301 | -77,519 |
Net Change In Cash | 96,735 | 48,579 | 18,256 | 9,330 |
Cost of Revenue | 55,479 | |||
Free Cash Flow | -32,994 | -7,731 | -64,308 | -86,029 |
Cash | 76,333 | 109,107 | 112,584 | 85,209 |
Basic Shares | 52,989 | 37,585 | 30,895 | 22,386 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.32 |
2024-06-30 | -$0.33 |
2024-03-31 | -$0.24 |
2023-12-31 | $0.96 |
